<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966105</url>
  </required_header>
  <id_info>
    <org_study_id>IOSI-EMA-007</org_study_id>
    <nct_id>NCT03966105</nct_id>
  </id_info>
  <brief_title>Prevalence of Wild Type ATTR</brief_title>
  <official_title>Prevalence of Amyloidosis in Patients With Lumbar Spinal Stenosis or Carpal Tunnel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncology Institute of Southern Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ente Ospedaliero Cantonale, Bellinzona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oncology Institute of Southern Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, observational, single-centre, non-interventional study aiming at reporting the
      prevalence of ATTRwt in patients with carpal tunnel syndrome (CTS) and/or lumbar spinal
      stenosis (LSS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include patients that receive surgical management and treatment for CTS and
      LSS, and will consist in the prospective, longitudinal collection of peripheral blood, urine
      samples, tissue biopsies and clinical data. The results of the project could provide a future
      benefit for patients with the same condition by: i) identifying accessible and sensitive
      biomarkers for the identification of patients at risk for having an underlying ATTRwt; ii)
      optimizing the therapeutic strategies in an era of innovative but cost-intensive treatments;
      iii) provide the proof of principle for a regular follow-up of patients who eventually will
      become symptomatic for overt organ ATTRwt involvement; and iv) providing the rationale for
      future studies based on early access disease-modifying approaches.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Report the prevalence of ATTRwt in patients with CTS and/or LSS.</measure>
    <time_frame>2 years</time_frame>
    <description>Prevalence of ATTRwt in a prospective population.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Transthyretin Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Patients with CTS surgery indication</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with LSS surgery indication</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HE and Congo red staining</intervention_name>
    <description>Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.</description>
    <arm_group_label>Patients with CTS surgery indication</arm_group_label>
    <arm_group_label>Patients with LSS surgery indication</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective population of 200 patients undergoing CTS surgery and 100 patients undergoing
        LSS surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female â‰¥ 50 years-old with indication of surgery treatment according to local
             standards for Carpal tunnel syndrome (CTS) documented at ENMG evaluation and/or o
             Lumbar spinal stenosis (LSS) confirmed by MRI

          -  Availability of the baseline and follow-up annotations

          -  Informed consent will be obtained from the patient before any study related procedures

        Exclusion Criteria:

          -  Previous diagnosis of amyloidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adalgisa Condoluci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Institute of Southern Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adalgisa Condoluci, MD</last_name>
    <phone>+41(0)918118105</phone>
    <email>adalgisa.condoluci@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bernhard Gerber, PD</last_name>
    <phone>+41(0)918118186</phone>
    <email>bernhard.gerber@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <state>Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Adalgisa Condoluci, MD</last_name>
      <phone>+41(0)918118105</phone>
      <email>adalgisa.condoluci@eoc.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oncology Institute of Southern Switzerland</investigator_affiliation>
    <investigator_full_name>Adalgisa Condoluci</investigator_full_name>
    <investigator_title>MD, Resident Physician</investigator_title>
  </responsible_party>
  <keyword>wild-type</keyword>
  <keyword>carpal tunnel syndrome</keyword>
  <keyword>lumbar spinal stenosis</keyword>
  <keyword>prevalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

